Tempus AI Stock Jumps As Mizuho Starts Coverage, Earnings Scheduled For Next Week
Tempus AI Inc. (NASDAQ:TEM) shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence firm.
Analyst Bradley Bowers started coverage with an Outperform rating and a price forecast of $100.
On Wednesday, the company announced a new HRD-RNA algorithm, an AI-driven tool aimed at enhancing the detection of homologous recombination deficiency in tumors.
HRD-RNA Algorithm Boosts Tempus AI Shares
The HRD-RNA algorithm analyzes gene expression to identify patients who could benefit from platinum-based chemotherapy or PARP inhibitors. In a real-world validation study, patients with HRD-RNA-positive metastatic pancreatic cancer treated with first-line platinum-based regimens experienced a significant reduction in mortality risk compared to those receiving non-platinum therapies.
Tempus plans to make this test clinically available later this year, with Chief Development Officer Halla Nimeiri highlighting that the algorithm offers a more functional view of HRD status by examining the transcriptome rather than just the genome.
Last week, Median Technologies announced its non-exclusive distribution agreement with Tempus AI to distribute eyonis LCS to U.S. imaging providers through the Tempus Pixel platform and support implementation, customer onboarding and workflow integration.
The broader market is seeing mixed performance today, with sectors like Energy and Industrials gaining, while Technology stocks are generally lower. This backdrop suggests that Tempus’s rise is more about its specific advancements rather than a reflection of broader market trends.
Tempus AI Stock Faces Bearish Medium-Term Trend
Currently, the stock is trading 3.84% above its 20-day simple moving average (SMA) but is 8% below its 50-day SMA and 19.3% below its 100-day SMA, indicating a bearish trend in the medium to long term. Over the past 12 months, shares have decreased 31.21% and are currently positioned closer to their 52-week lows than highs.
The RSI is at 43.64, which is considered neutral territory, while the MACD shows a value of -3.5906, below its signal line at -3.4326, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock's near-term performance.
- Key Resistance: $66
- Key Support: $59
Anticipation Builds for Tempus AI’s Earnings Report
The countdown is on: Tempus AI is set to report earnings on Feb. 24.
- EPS Estimate: Loss of 14 cents (Up from loss of 18 cents)
- Revenue Estimate: $364.45 million (Up from $200.68 million)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $78.06. Recent analyst moves include:
- Mizuho: Initiated with Outperform (Target $100 on Feb. 19)
- Baird: Initiated with Outperform (Target $59 on Feb. 17)
- Canaccord Genuity: Buy (Lowers Target to $80 on Dec. 22, 2025)
TEM’s Significant Weight in ARK ETFs
- ARK Innovation ETF (NYSE:ARKK): 5.07% Weight
- ARK Genomic Revolution ETF (BATS:ARKG): 8.63% Weight
TEM Price Action: Tempus AI shares were up 4.22% at $58.53 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Piotr Swat via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Metals fade as long yields offset cooler inflation, lower Fed odds - Kitco PM Report
Bitwise brings NEAR to Wall Street – But the chart isn’t impressed
Synopsys and OpenAI reach AI chip design partnership, stock price surges over 7%
Synopsys has signed a multi-year legally binding agreement with OpenAI to jointly develop GPT-Synopsys, a model specifically trained and fine-tuned for chip design tasks. OpenAI will pay Synopsys a subscription fee for tool licensing, and both parties will share revenue based on improvements in chip design achieved by customers using the product.
How does Wall Street view the PCE? Goldman Sachs delays expectation for Fed rate hike
After the lower-than-expected US August PCE data was released, Goldman Sachs delayed its expectation for the Federal Reserve's second rate hike from October to December, and stated that it does not rule out the possibility that the Fed may eventually decide no further hikes are necessary. "New Fed Newsletter" Timiraos noted that the PCE does not change the previously known trend of rising inflation. Currently, the market prices in a 39% probability of a rate hike in October, down from 45% before the PCE release; and a 90% probability in December. The yield on 2-year US Treasury notes dipped slightly after the PCE announcement and then rebounded, while the 10-year yield continued to rise.
Crypto prices
More
